Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing, China.
Beijing Municipal Geriatric Medical Research Center, Beijing, People's Republic of China.
BMJ Open. 2023 Feb 3;13(2):e066181. doi: 10.1136/bmjopen-2022-066181.
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder over the last four decades, more evidence shows a high prevalence of sarcopenia in NAFLD that may influence disease severity. This meta-analysis aims to determine the association of sarcopenia with liver fibrosis and steatohepatitis in NAFLD.
We will conduct the literature search using Medline (via PubMed), Web of Science databases, EMBASE, Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews (from the date of inception to 1 May 2022). There will be no restriction to the publication year. Two reviewers will independently screen the articles and abstract key study characteristics. The outcome of this meta-analysis is the strength of association of sarcopenia with liver fibrosis and steatohepatitis in NAFLD. The STATA (V.14, StataCorp, 2015) will be used to carry out the statistical analysis. Comprehensive evaluation of bias risk and heterogeneity will be performed before data synthesis. Also, consistency and evidence quality will be assessed.
There will be no need of ethics approval as this systematic review is summary and analysis of existing literature. Final results may be presented in international conferences or a peer-reviewed journal.
CRD42022322685.
非酒精性脂肪性肝病（NAFLD）在过去四十年中已成为最常见的慢性肝病，越来越多的证据表明 NAFLD 中肌少症的患病率很高，这可能会影响疾病的严重程度。本荟萃分析旨在确定肌少症与 NAFLD 中肝纤维化和脂肪性肝炎的相关性。
我们将使用 Medline（通过 PubMed）、Web of Science 数据库、EMBASE、Cochrane 对照试验中心注册库和 Cochrane 系统评价数据库（从成立日期到 2022 年 5 月 1 日）进行文献检索。我们不会对出版年份进行限制。两名评审员将独立筛选文章并提取关键研究特征。本荟萃分析的结果是肌少症与 NAFLD 中肝纤维化和脂肪性肝炎的关联强度。将使用 STATA（V.14，StataCorp，2015）进行统计分析。在进行数据综合之前，将对偏倚风险和异质性进行全面评估。还将评估一致性和证据质量。
由于本系统评价是对现有文献的总结和分析，因此不需要伦理批准。最终结果可能会在国际会议或同行评议期刊上公布。
PROSPERO 注册号：CRD42022322685。
